Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ensem Therapeutics
AstraZeneca
Genmab
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
STORM Therapeutics LTD
Tubulis GmbH
Eli Lilly and Company
Neonc Technologies, Inc.
Ipsen
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
University of Washington
NYU Langone Health
Merus B.V.
Aulos Bioscience, Inc.
Memorial Sloan Kettering Cancer Center
Exscientia AI Limited
Amgen
University of California, Davis
One-carbon Therapeutics AB
Xinqiao Hospital of Chongqing
Radiopharm Theranostics, Ltd
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Washington University School of Medicine
Kura Oncology, Inc.
VM Oncology, LLC
Tanabe Pharma America, Inc.
Takeda
DualityBio Inc.
BicycleTx Limited
Roswell Park Cancer Institute
University of Pittsburgh
Volastra Therapeutics, Inc.
Dragonfly Therapeutics
Immunitas Therapeutics
University of Cincinnati
BeiGene
Sichuan Baili Pharmaceutical Co., Ltd.
LigaChem Biosciences, Inc.
Scancell Ltd
Hoffmann-La Roche
GI Innovation, Inc.
Taipei Veterans General Hospital, Taiwan
A2 Biotherapeutics Inc.
Incyte Corporation
Fudan University